NCT00378976View on ClinicalTrials.gov

HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

July 31, 2004

Conditions
HIV InfectionHerpes SimplexSexually Transmitted Diseases
Interventions
DRUG

valacyclovir

500 mg twice-daily oral

DRUG

matching placebo

twice daily as per experimental drug

Trial Locations (1)

Unknown

Asociacion Civil Impacta Salud y Educacion, Lima

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Asociación Civil Impacta Salud y Educación, Peru

OTHER

lead

University of Washington

OTHER

NCT00378976 - HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. | Biotech Hunter | Biotech Hunter